NA CRISPR Gene Detection and Diagnostics Market - Industry Trends and Forecast to 2029

The North America CRISPR gene detection and diagnostic market is projected to register a CAGR of 19.6% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2019, the base year of calculation is 2021 and the forecast period is 2022 to 2029

Market Segmentation: 
North America CRISPR Gene Detection and Diagnostic Market, By Class (Class 1- Multiple Effector Proteins and Class 2 -Single CrRNA-Binding Protein), Products & Services (Products and Services), Application (Biomedical Diagnostics, Genome Engineering, Drug Discovery, Agricultural Applications and Others), Workflow (Sample Preparation, Pre-Amplification, CrRNA, Cas Enzymes and Sensing), End User (Hospitals, Diagnostic Centers, Biotechnology Companies, Academic and Research Institutes and Others), Distribution Channel (Direct Tender, Retail Sales), Country (U.S., Canada, Mexico) Industry Trends and Forecast to 2029

Some of the major factors contributing to the growth of the North America CRISPR gene detection and diagnostic market are:

• The rise in prevalence and incidence of chronic diseases

• Rise in investment in research and development

Market Players:

Some of the major players operating in the market are:

• GenScript
• OriGene Technologies, Inc.
• Applied StemCell
• GeneCopoeia, Inc.
• Agilent Technologies, Inc.
• Synthego, BioVision Inc.
• Hera Biolabs
• Cellecta, Inc.
• New England Biolabs
• 10x Genomics
• ADDGENE
• CasTag Biosciences
• Merck KGaA
• Integrated DNA Technologies, Inc. (A subsidiary of Danaher)
• Thermo Fisher Scientific Inc.